PASSAGE BIO INC

Company Overview

Passage Bio is a clinical-stage genetic medicines company developing one-time AAV-based gene therapies for neurodegenerative diseases, with lead program PBFT02 (AAV1 delivered ICM) targeting progranulin deficiency in FTD-GRN and planned expansion into ALS and select Alzheimer’s populations. The company has reported robust CSF PGRN biomarker increases in early cohorts but has also disclosed thrombotic safety events and a transient hepatotoxicity episode that prompted protocol and prophylaxis changes. Operationally Passage relies on a hybrid model with in‑house R&D and outsourced manufacturing (Catalent), has out‑licensed pediatric programs to Gemma for upfront/milestone payments, and recently executed a major portfolio and workforce restructuring to extend runway (management estimates funding into Q1 2027). Key near‑term value drivers and risks are clinical/regulatory readouts, manufacturing comparability discussions, out‑license milestones/royalties, and need for additional financing.

Executive Compensation Practices

As a small, clinical‑stage biotechnology company, executive pay is likely equity‑heavy and tied to clinical and regulatory milestones (IND/registrational design input, Dose 2 and pivotal readouts), with bonus and long‑term incentive designs that reward successful trial progress and de‑risking events such as out‑licenses. Recent MDA disclosures show materially lower R&D/G&A and reduced share‑based compensation after the January 2025 workforce reduction and out‑licensing transactions, so the compensation committee is likely prioritizing cash preservation, smaller annual equity grants, and targeted retention awards for critical technical staff. One‑time payments from out‑licenses and milestone receipts (Gemma/Penn) can also produce ad hoc cash or bonus payments; however, ongoing reliance on future financings means future executive awards may be structured to limit near‑term cash outflows and to align with fundraising and dilution considerations.

Insider Trading Considerations

Insider trading activity at Passage Bio will tend to cluster around material clinical and regulatory milestones (interim biomarker updates, Dose 2/registrational design feedback, manufacturing comparability talks) and around financing events (ATM sales, equity raises) because those events materially change the company’s cash runway and valuation. Given the safety signals (venous sinus thromboses, hepatotoxicity) and active protocol amendments, insiders are subject to heightened constraints on trading during blackout windows and must be careful about material nonpublic information—many insiders will rely on pre‑arranged Rule 10b5‑1 plans and timely Form 4 filings. Monitor insider option exercises and any sales following out‑license milestone receipts or restructuring announcements: routine diversification sales are common in biotech, but clustered or large sales shortly before negative announcements can be informative to traders and researchers.